In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Tonix Pharmaceuticals Holding Corp’s stock clocked out at $10.95, down -8.37% from its previous closing price of $11.95. In other words, the price has decreased by -$8.37 from its previous closing price. On the day, 0.77 million shares were traded.
Ratios:
To gain a deeper understanding of TNXP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 3.33. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.08.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4. ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Stock Price History:
Over the past 52 weeks, TNXP has reached a high of $1248.00, while it has fallen to a 52-week low of $10.82. The 50-Day Moving Average of the stock is -60.70%, while the 200-Day Moving Average is calculated to be -89.70%.
Shares Statistics:
A total of 155.63M shares are outstanding, with a floating share count of 5.59M. Insiders hold about 0.00% of the company’s shares, while institutions hold 3.13% stake in the company.
Earnings Estimates
The dynamic stock of Tonix Pharmaceuticals Holding Corp (TNXP) is currently being evaluated by a team of 1 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$640, with high estimates of -$640 and low estimates of -$640.
Analysts are recommending an EPS of between -$3552 and -$3552 for the fiscal current year, implying an average EPS of -$3552. EPS for the following year is -$2784, with 1 analysts recommending between -$2784 and -$2784.
Revenue Estimates
In the current quarter, 2 analysts expect revenue to total $3.2M. It ranges from a high estimate of $4.1M to a low estimate of $2.3M. As of the current estimate, Tonix Pharmaceuticals Holding Corp’s year-ago sales were $3.78MFor the next quarter, 2 analysts are estimating revenue of $4.2M. There is a high estimate of $4.2M for the next quarter, whereas the lowest estimate is $4.2M.
A total of 2 analysts have provided revenue estimates for TNXP’s current fiscal year. The highest revenue estimate was $15.8M, while the lowest revenue estimate was $9.8M, resulting in an average revenue estimate of $12.8M. In the same quarter a year ago, actual revenue was $7.77MBased on 2 analysts’ estimates, the company’s revenue will be $13.35M in the next fiscal year. The high estimate is $17.2M and the low estimate is $9.5M.
